In spastin mouse model-derived neurons and patient-derived cells of HSP, spastin levels can be pharmacologically restored by inhibiting its neddylation-mediated degradation, revealing a novel therapeutic target for SPG4-HSP treatment. The gene discussed is SPAST; the disease is hereditary spastic paraplegia.